Software Daily Summary: What Happened on October 16, 2026

SecureBio calls for testing AI biological-design capabilities

SecureBio said AI-enabled biological design could increase the potential harm from engineered pathogens and called for capability evaluations and safeguards before systems reach potentially dangerous thresholds.1 AI models can help researchers screen biological variants computationally and select candidates for lab testing, potentially shortening optimization timelines.1

Researchers have used Evo models to generate viable ΦX174 bacteriophage genomes not previously detected in nature, though the degree of novelty is disputed.1 SecureBio said current AI tools still have difficulty predicting viral epistasis, or how genetic changes interact, and designing entirely novel viruses.1

The author cited a 2025 Nuclear Threat Initiative statement, signed by more than 40 experts, warning that AI tools might enable designs for pathogens more dangerous than those found in nature.1 SecureBio said its AI work develops evaluations of frontier-model capabilities, while its Detection work uses pathogen-agnostic surveillance to identify known and novel pathogens.1

Pharma AI commentary emphasizes governance and human review

MERGE executive Pat McGloin said pharma companies should choose which problems AI will address and build secure systems with trusted data, approved content and regulatory oversight.2 He said generative AI may improve personalization but cannot create human-centered engagement on its own.2

McGloin said companies use AI to support medical, legal and regulatory review, not bypass it, and people retain final approval.2 MERGE has been piloting systems that assemble candidate content from pre-approved materials and flag deviations for human review, he said.2

Pharmaceutical Executive's analysis said biopharma discussions are shifting from fascination with AI to its purpose, trust, oversight and measurable effects.3 AI-supported quality management could connect thousands of dispersed signals to flag supply or business risks earlier, the analysis said.3

Also worth knowing

• P

  Pharmaphorum published an October 2026 news watch on AI in drug discovery and development.4

• P

  A Pharmaphorum headline asserted that better analytics leads to fewer regulator questions.5

Also published

• When Experience, Evidence, and AI Disagree in Pharma, What Should Leaders Do? Pharmaceutical Executive